上海家化联合股份有限公司 独立董事提名人声明 提名人上海家化（集团）有限公司，现提名李明辉为上海家 化联合股份有限公司第九届董事会独立董事候选人，并已充分了 解被提名人职业、学历、职称、详细的工作经历、全部兼职、有 无重大失信等不良记录等情况。被提名人已同意出任上海家化联 合股份有限公司第九届董事会独立董事候选人（参见该独立董事 候选人声明）。 提名人认为，被提名人具备独立董事任职资格，与上海家化 联合股份有限公司之间不存在任何影响其独立性的关系，具体声 明如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、 行政法规、规章及其他规范性文件，具有 5 年以上法律、经济、 会计、财务、管理或者其他履行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训 证明材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章 以及公司规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的 1 规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资 ...

上海家化联合股份有限公司 独立董事候选人声明 本人夏海通、刘晓彬，已充分了解并同意由提名人上海家化 （集团）有限公司提名为上海家化联合股份有限公司（以下简称 "该公司"）第九届董事会独立董事候选人。本人公开声明，本 人具备独立董事任职资格，保证不存在任何影响本人担任该公司 独立董事独立性的关系，具体声明如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、部门规章及其他规范性文件，具有 5 年以上法律、经济、 会计、财务、管理或者其他履行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训 证明材料。 二、本人任职资格符合下列法律法规和部门规章以及公司规 章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的 规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定； 1 （四）中共中央纪委、中共中央组织部《关于规范中管干部 辞去公职或者退（离）休后担任上市公司、基金管理公司独立董 事、独立监事的通知》的规定（如适 ...

证券代码：600315 证券简称：上海家化 公告编号：2025-030 (五)网络投票的系统、起止日期和投票时间。 上海家化联合股份有限公司 关于召开2025年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 6 月 4 日 13 点 30 分 召开地点：上海市虹口区保定路 527 号八楼会议室 股东会召开日期：2025年6月4日 本次股东会采用的网络投票系统：上海证券交易所股东大会网络投票系 统 (一)股东会类型和届次 2025年第一次临时股东会 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 4 日 至2025 年 6 月 4 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25 ...

证券简称：上海家化 证券代码：600315 编号：临 2025-026 1、审议通过关于修订《公司章程》暨不再设置监事会的议案并提交股东会 审议 表决情况：7 票同意，0 票反对，0 票弃权，通过本议案。 具体内容请详见公司本日披露的《上海家化联合股份有限公司关于修订<公 司章程>暨不再设置监事会的公告》（临 2025-027），修订后的《公司章程》请 见上海证券交易所网站。 该议案尚需提交股东会审议。 2、审议通过关于修订《上海家化股东会议事规则》的议案并提交股东会审 议 表决情况：7 票同意，0 票反对，0 票弃权，通过本议案。 上海家化联合股份有限公司 八届二十六次董事会决议公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 上海家化联合股份有限公司八届二十六次董事会于2025年5月19日以通讯方 式召开，会议通知于2025年5月14日通过邮件方式发出。本次会议应参加董事7 人，实际参加董事7人。本次会议的召开和表决程序符合《公司法》及《公司章 程》的有关规定。 二、董事会会议审 ...

Market Performance - The market rebounded last week, with the China Securities Xinhua National Brand Index rising by 0.94% to 1666.03 points [1] - The Shanghai Composite Index increased by 0.76%, the Shenzhen Component Index by 0.52%, the ChiNext Index by 1.38%, and the CSI 300 Index by 1.12% [1] Strong Stock Performances - Notable strong performers in the brand index included BGI Genomics, which rose by 17.27%, and Yiling Pharmaceutical, which increased by 9.81% [1] - Other significant gainers included Stone Technology and Marubi Biological, which rose by 7.18% and 6.79%, respectively [1] Year-to-Date Stock Gains - Since the beginning of 2025, Marubi Biological has surged by 60.82%, leading the gains, followed by Shanghai Jahwa with a 46.72% increase and BGI Genomics with a 34.45% rise [2] - Other stocks with notable increases include Anji Technology, Xintai, and Weir Shares, each rising over 20% [2] Market Outlook - Institutions expect the market to refocus on domestic economic fundamentals, with a positive policy response anticipated [2][3] - The current market is viewed as being in a high cost-performance range, with significant policy support expected to stabilize the economy and market [2] Economic Data Focus - Attention is drawn to upcoming economic data, particularly export performance and the sustainability of the export supply chain recovery [3] - The prevailing market conditions are supported by policy measures and liquidity easing, which are expected to bolster the stability of the domestic economy and capital markets [3]

Core Insights - The analysis focuses on the financial performance of 17 representative listed companies in the daily chemical skincare industry, highlighting the significant disparity between sales gross margin and net profit margin [1][2]. Group 1: Financial Performance - In 2024, nearly 80% of the selected companies reported a sales gross margin exceeding 50%, with some companies achieving gross margins over 75% [1][2]. - The industry shows a trend of high gross margins but low net profit margins, with 70% of companies having net profit margins below 15% [1][2]. - The top three companies in terms of sales gross margin are Jinbo Biological (92.02%), Juzhi Biological (82.09%), and Fulejia (81.73%) [2]. Group 2: Sales Net Margin Analysis - The leading companies in sales net margin are Jinbo Biological (50.68%), Juzhi Biological (37.22%), and Fulejia (32.78%) [4]. - Companies such as Jiaheng Household Chemicals (-2.57%), Shanghai Household Chemicals (-14.67%), and Yixian E-commerce (-20.9%) exhibit significantly low net profit margins [4]. Group 3: Industry Challenges - The high sales expenses in the daily chemical skincare industry are identified as a primary reason for the low net profit margins, as substantial marketing costs erode profits [2]. - Qing Song Co. has the lowest sales gross margin at 17.42%, attributed to its positioning as an OEM, facing intense competition from thousands of domestic cosmetic OEMs [6]. - Yixian E-commerce's negative net profit margin of -20.9% is linked to ongoing losses and high marketing expenditures [6].

Core Insights - The performance of the daily chemical skincare industry in 2024 is generally pessimistic, with only 6 out of 17 selected companies achieving both revenue and net profit growth [1][2][4] - Notably, 4 companies reported losses, including Yatsen E-commerce, Jiaheng Cosmetics, Furuida, and Shanghai Jahwa, with Yatsen E-commerce experiencing continuous losses since its IPO in 2020, totaling over 6.5 billion yuan in losses [1][2][4] Revenue and Profit Analysis - Among the 17 companies analyzed, 6 companies reported a decline in both revenue and net profit, including Qingsong Co., Kesi Co., Shuiyang Co., Furuida, and Huaxi Biological [4][5] - The companies with revenue and net profit growth include Jinbo Biological (revenue up 84.92%, net profit up 144.27%), Shangmei Co. (revenue up 62.1%), and Juzi Biological (revenue up 57.2%) [2][7][9] - Companies with revenue but no profit growth include Lafang Co. (revenue 889 million yuan, net profit down 36.84%), Beitaini (revenue 5.736 billion yuan, net profit down 33.53%), and Fulejia (revenue 2.017 billion yuan, net profit down 11.77%) [2][4] Losses Overview - Yatsen E-commerce reported total revenue of 3.393 billion yuan, a slight decline of 0.63%, with a net profit loss of 710 million yuan [5][6] - Shanghai Jahwa's revenue was 5.679 billion yuan, down 13.93%, with a net profit loss of 833 million yuan, marking a significant decline of 266.6% [5][6] - Jiaheng Cosmetics reported revenue of 923 million yuan, down 9.13%, with a net profit loss of 24 million yuan, a decline of 159% [5][6] Performance Rankings - The top three companies in revenue growth are Jinbo Biological, Shangmei Co., and Juzi Biological, with growth rates of 84.92%, 62.1%, and 57.2% respectively [7] - The bottom three in revenue growth are Shanghai Jahwa, Furuida, and Jiaheng Cosmetics, with declines of 13.93%, 13.02%, and 9.13% respectively [7] - In terms of net profit growth, the top three are Jinbo E-commerce, Shangmei Co., and Juzi Biological, with growth rates of 144.27%, 74%, and 42.4% respectively [9]

（原标题：美容护理行业5月15日资金流向日报） 沪指5月15日下跌0.68%，申万所属行业中，今日上涨的有4个，涨幅居前的行业为美容护理、煤炭，涨 幅分别为3.68%、0.42%。美容护理行业位居今日涨幅榜首位。跌幅居前的行业为计算机、通信，跌幅 分别为2.97%、2.45%。 美容护理行业今日上涨3.68%，全天主力资金净流入3.86亿元，该行业所属的个股共31只，今日上涨的 有28只，涨停的有8只；下跌的有3只。以资金流向数据进行统计，该行业资金净流入的个股有23只，其 中，净流入资金超3000万元的有9只，净流入资金居首的是福瑞达，今日净流入资金1.11亿元，紧随其 后的是青松股份、洁雅股份，净流入资金分别为6854.51万元、4824.24万元。美容护理行业资金净流出 个股中，净流出资金居前的有青岛金王、稳健医疗、上海家化，净流出资金分别为1.72亿元、1446.11万 元、1146.58万元。（数据宝） | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 600223 | 福瑞达 | 10. ...

Group 1 - The A-share cosmetics sector experienced a significant rise in the afternoon, with Huaye Fragrance hitting the daily limit up [1] - Furuida, Lafang Home, and Bawi Co. previously reached their daily limit, while Qingsong Co. surged over 10% [1] - Other companies such as Shanghai Jahwa, Proya, Jiaheng Home, Jinsong New Materials, and Beitaini also saw increases [1]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 27.26 CNY [3][7]. Core Views - The company is expected to experience a recovery starting in 2025, driven by strategic reforms and a new management team [6]. - The introduction of an equity incentive plan aims to motivate key personnel and align their interests with the company's performance [6]. - The company anticipates a double-digit revenue growth in 2025 following a challenging 2024 [6]. Financial Performance Summary - Revenue for 2023 was 6,598 million CNY, with a projected decline to 5,679 million CNY in 2024, followed by a recovery to 6,272 million CNY in 2025, representing a 10.4% growth [3][10]. - The net profit attributable to the parent company is expected to recover from a loss of 833 million CNY in 2024 to a profit of 321 million CNY in 2025, reflecting a 138.6% increase [3][10]. - Earnings per share (EPS) are projected to be 0.48 CNY in 2025, 0.69 CNY in 2026, and 0.89 CNY in 2027 [3][7]. Product and Channel Performance - In 2024, revenue from personal care, beauty, innovation, and overseas businesses is expected to decline by 3.4%, 29.8%, 19.4%, and 11.4% respectively, indicating pressure on the beauty segment [6]. - Online and offline revenue is projected to decrease by 9.7% and 17% respectively in 2024 [6]. Margin Analysis - The gross margin is expected to decline to 57.6% in 2024, with personal care showing a slight increase while beauty and overseas segments face declines [6]. - The net profit margin is projected to be -14.7% in 2024, reflecting significant challenges [6]. Strategic Initiatives - The company is focusing on online transformation and strategic adjustments in offline channels to adapt to industry changes [6]. - The management aims to enhance online operational capabilities, particularly in interest e-commerce and emerging platforms [6].